Background/Aims Galectin-3 plays a key pathogenic role in cardiac hypertrophy and heart failure. The present study aimed to investigate the effects of galectin-3 on cardiomyopathy – related factors and cardiac contractility in a rat model of cirrhotic cardiomyopathy.
Methods Rats were divided into two sets, one for a functional study, the other for cardiac contractile-related protein evaluation. There were four groups in each set: sham operated and sham plus N-acetyllactosamine (N-Lac, a galectin-3 inhibitor; 5 mg/kg); bile duct ligated (BDL) and BDL plus N-Lac. Four weeks after surgery, ventricular level of galectin-3, collagen I and III ratio, tumor necrosis factor alpha (TNFα), and brain natriuretic peptide (BNP) were measured either by Western blots or immunohistochemistry or enzyme-linked immunosorbent assay. Blood pressure was measured by polygraph recorder. Cardiomyocyte contractility was measured by inverted microscopy.
Result s: Galectin-3 and collagen I/III ratio were significantly increased in cirrhotic hearts. TNFα and BNP were significantly increased in BDL serum and heart compared with sham controls. Galectin-3 inhibitor significantly decreased galectin-3, TNFα, and BNP in cirrhotic hearts but not in sham controls. N-Lac also significantly improved the blood pressure, and systolic and diastolic cardiomyocyte contractility in cirrhotic rats but had no effect on sham controls.
Conclusion Increased galectin-3 in the cirrhotic heart significantly inhibited contractility via TNFα. Inhibition of galectin-3 decreased the cardiac content of TNFα and BNP and reversed the decreased blood pressure and depressed contractility in the cirrhotic heart. Galectin-3 appears to play a pathogenic role in cirrhotic cardiomyopathy.
Citations
Citations to this article as recorded by
Apoptosis in Cardiac Conditions Including Cirrhotic Cardiomyopathy Fengxue Yu, Dae Gon Ryu, Ki Tae Yoon, Hongqun Liu, Samuel S. Lee International Journal of Molecular Sciences.2025; 26(13): 6423. CrossRef
Cirrhotic Cardiomyopathy: Bridging Hepatic and Cardiac Pathophysiology in the Modern Era Dragoș Lupu, Camelia Cornelia Scârneciu, Diana Țînț, Cristina Tudoran Journal of Clinical Medicine.2025; 14(17): 5993. CrossRef
Galectin-3: A Multitasking Protein Linking Cardiovascular Diseases, Immune Disorders and Beyond Mariarosaria Morello, Gisella Titolo, Saverio D’Elia, Silvia Caiazza, Ettore Luisi, Achille Solimene, Chiara Serpico, Andrea Morello, Francesco Natale, Paolo Golino, Plinio Cirillo, Giovanni Cimmino Targets.2025; 3(4): 34. CrossRef
Galectin-3 as a therapeutic target in pulmonary hypertension: Molecular mechanisms, drug development directions, and emerging clinical applications Antonín Sedlář, Pavla Bojarová, František Kolář, Vladimír Křen, Lucie Bačáková Biomedicine & Pharmacotherapy.2025; 193: 118756. CrossRef
Cardiomyopathy in cirrhosis: From pathophysiology to clinical care Hongqun Liu, Jwan A. Naser, Grace Lin, Samuel S. Lee JHEP Reports.2024; 6(1): 100911. CrossRef
Cirrhotic cardiomyopathy: Pathogenesis, clinical features, diagnosis, treatment and prognosis Francisca Almeida, Alexandra Sousa Revista Portuguesa de Cardiologia.2024; 43(4): 203. CrossRef
Therapies for Cirrhotic Cardiomyopathy: Current Perspectives and Future Possibilities Hongqun Liu, Daegon Ryu, Sangyoun Hwang, Samuel S. Lee International Journal of Molecular Sciences.2024; 25(11): 5849. CrossRef
Role of Galectin in Cardiovascular Conditions including Cirrhotic Cardiomyopathy Hongqun Liu, Sang-Youn Hwang, Samuel S. Lee Pharmaceuticals.2023; 16(7): 978. CrossRef
Chenodeoxycholic Acid Improves Embryo Implantation and Metabolic Health through Modulating Gut Microbiota–Host Metabolites Interaction during Early Pregnancy Meixia Chen, Ying Zhao, Haifeng Ji, Lu Li, Hui Liu, Sixin Wang, Dongyan Zhang, Jingdong Yin, Jing Wang, Xin Zhang Antioxidants.2023; 13(1): 8. CrossRef
Temporal profile of cerebrospinal fluid galactin-3 and associated cytokine responses after severe traumatic brain injury in patients: a retrospective study Melisa Cetin, Ping Yip, Zhou-Hao Liu Future Healthcare Journal.2023; 10: S18. CrossRef
Temporal profile of cerebrospinal fluid galactin-3 and associated cytokine responses after severe traumatic brain injury in patients: a retrospective study Melisa Cetin, Ping Yip, Wing Sze Leung, Zhou-Hao Liu Clinical Medicine.2023; 23(6): 81. CrossRef
Pathogenic Mechanisms Underlying Cirrhotic Cardiomyopathy Hongqun Liu, Henry H. Nguyen, Ki Tae Yoon, Samuel S. Lee Frontiers in Network Physiology.2022;[Epub] CrossRef
Collagen-binding fibroblast growth factor ameliorates liver fibrosis in murine bile duct ligation injury Qiangqiang Shi, Susu Wei, Zhi Chao Li, Jing Xu, Yaxin Li, Chuanlong Guo, Xianggen Wu, Chunying Shi, Guohu Di Journal of Biomaterials Applications.2022; 37(5): 918. CrossRef
Nonselective beta-adrenergic blocker (NSBB) therapy for the prevention of initial and recurrent gastrointestinal bleeding in cirrhotic patients with gastroesophageal varices has been used for the past four decades. NSBB therapy is considered the cornerstone of treatment for varices, and has become the standard of care. However, a 2010 study from the group that pioneered β-blocker therapy suggested a detrimental effect of NSBBs in decompensated cirrhosis, especially in patients with refractory ascites. Since then, numerous additional studies have incompletely resolved whether NSBBs are deleterious, although more recent evidence weighs against a harmful effect. The possibility of a “therapeutic window” has also been raised. We aimed to review the literature to analyze the pros and cons of using NSBBs in patients with cirrhosis, not only with respect to bleeding or mortality but also to other potential benefits and risks. β-blockers are highly effective in preventing first bleeding and recurrent bleeding. Furthermore, NSBBs improve congestion/ischemia of the gut mucosa, decrease intestinal permeability, and therefore indirectly alleviate systemic inflammation. β-blockers shorten the electrocardiographic prolonged QTc interval and may also decrease the incidence of hepatocellular carcinoma. On the other hand, the possibility of deleterious effects in cirrhosis has not been completely eliminated. NSBBs may be associated with an increased risk of portal vein thrombosis, although this could be correlational artifact. Overall, we conclude that β-blockers in cirrhosis are much more of a friend than enemy.
Citations
Citations to this article as recorded by
Potential therapies for acute‐on‐chronic liver failure Maura A. Morrison, Florent Artru, Francesca M. Trovato, Evangelos Triantafyllou, Mark J. McPhail Liver International.2025;[Epub] CrossRef
Advancements of direct oral anticoagulants in cirrhotic individuals with portal vein thrombosis Zhiqian Liu, Xiying Yang, Haitao Jiang, Rui Xie, Hong Wang Clinics and Research in Hepatology and Gastroenterology.2025; 49(4): 102553. CrossRef
Cirrhotic Cardiomyopathy: Bridging Hepatic and Cardiac Pathophysiology in the Modern Era Dragoș Lupu, Camelia Cornelia Scârneciu, Diana Țînț, Cristina Tudoran Journal of Clinical Medicine.2025; 14(17): 5993. CrossRef
Principles of Non-selective Beta-blocker Usage for Cirrhosis-associated Complications Daisy K. Maclaine, Kosha J. Mehta SN Comprehensive Clinical Medicine.2025;[Epub] CrossRef
Cardiomyopathy in cirrhosis: From pathophysiology to clinical care Hongqun Liu, Jwan A. Naser, Grace Lin, Samuel S. Lee JHEP Reports.2024; 6(1): 100911. CrossRef
Therapies for Cirrhotic Cardiomyopathy: Current Perspectives and Future Possibilities Hongqun Liu, Daegon Ryu, Sangyoun Hwang, Samuel S. Lee International Journal of Molecular Sciences.2024; 25(11): 5849. CrossRef
Novel approaches in the medical management of compensated cirrhosis Antonio Moreno-Loro, Álvaro Giráldez, Fernando Jiménez, Ignacio López-Bueno, Alberto Pérez-Ramírez, Manuel Romero-Gómez Expert Review of Gastroenterology & Hepatology.2024; 18(6): 239. CrossRef
Features of the course of hepatorenal syndrome in decompensated portal hypertension (case report) M.I. Tutchenko, D.V. Rudyk, M.S. Besedinskyi, S.L. Chub, Yu.V. Nerushchenko GASTROENTEROLOGY.2024; 58(2): 151. CrossRef
Microarray analysis demonstrates up-regulation of the endothelin-1 gene with compensatory down-regulation of the ETA receptor gene in human portal vein Nicola E. Owen, Thomas L. Williams, Janet J. Maguire, Rhoda E. Kuc, Emma E. Davenport, Anthony P. Davenport Bioscience Reports.2024;[Epub] CrossRef
The effect of propranolol on gastrointestinal motility and permeability in patients with cirrhosis and significant portal hypertension Elias Xirouchakis, Hariklia Kranidioti, Emilia Hadziyanni, Anastasia Kourikou, Christos Reppas, Maria Vertzoni, Nikolaos Papadopoulos, Melanie Deutsch, George Papatheodoridis, Spilios Manolakopoulos BMC Gastroenterology.2024;[Epub] CrossRef
Review article: diagnosis, pathophysiology and management of atrial fibrillation in cirrhosis and portal hypertension Bert Vandenberk, Mario H. Altieri, Hongqun Liu, Satish R. Raj, Samuel S. Lee Alimentary Pharmacology & Therapeutics.2023; 57(3): 290. CrossRef
Non-invasive tests-based risk stratification: Baveno VII and beyond Georg Semmler, Mathias Jachs, Mattias Mandorfer Clinical and Molecular Hepatology.2023; 29(1): 105. CrossRef
Correspondence on Editorial regarding “Baveno-VII criteria to predict decompensation and initiate non-selective beta-blocker in compensated advanced chronic liver disease patients” Yu Jun Wong, Sanchit Sharma, Giulia Tosetti, Xiaolong Qi, Massimo Primignani Clinical and Molecular Hepatology.2023; 29(1): 188. CrossRef
Noninvasive risk assessment of hepatic decompensation in patients with hepatitis B virus‐related liver cirrhosis David Sooik Kim, Beom Kyung Kim, Jae Seung Lee, Hye Won Lee, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Nikolaos Pyrsopoulos, Seung Up Kim Journal of Gastroenterology and Hepatology.2023; 38(8): 1372. CrossRef
Dysregulated Calcium Handling in Cirrhotic Cardiomyopathy Sang Youn Hwang, Hongqun Liu, Samuel S. Lee Biomedicines.2023; 11(7): 1895. CrossRef
How to suspect the presence of high‐risk esophageal varices and when to start endoscopic surveillance in children with biliary atresia? Ujjal Poddar, Arghya Samanta, Moinak Sen Sarma, Basant Kumar, Richa Lal, Anshu Srivastava, Vijay Datta Upadhyaya, Surender Kumar Yachha, Ankur Mandelia Journal of Gastroenterology and Hepatology.2023; 38(9): 1610. CrossRef
Role of Galectin in Cardiovascular Conditions including Cirrhotic Cardiomyopathy Hongqun Liu, Sang-Youn Hwang, Samuel S. Lee Pharmaceuticals.2023; 16(7): 978. CrossRef
Non-selective beta-blockers and the incidence of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis Xinyi He, Zimo Zhao, Xi Jiang, Yan Sun Frontiers in Pharmacology.2023;[Epub] CrossRef
Portal vein thrombosis in cirrhosis: exploring the uncharted waters P Anirvan Journal of Gastroenterology and Hepatology.2023; 38(10): 1855. CrossRef
The Intestinal Microbiota in the Development of Chronic Liver Disease: Current Status Josip Stojic, Michał Kukla, Ivica Grgurevic Diagnostics.2023; 13(18): 2960. CrossRef
Nonselective beta-blockers may lead to stage 2 acute kidney injury and waitlist mortality in child class C cirrhosis Mason Lai, Cynthia Fenton, Jin Ge, Jessica Rubin, Jennifer C. Lai, Giuseppe Cullaro Hepatology Communications.2023;[Epub] CrossRef
Hepatorenal syndrome: Current concepts and future perspectives Chan-Young Jung, Jai Won Chang Clinical and Molecular Hepatology.2023; 29(4): 891. CrossRef
In severe alcohol‐related hepatitis, acute kidney injury is prevalent, associated with mortality independent of liver disease severity, and can be predicted using IL‐8 and micro‐RNAs Luke D. Tyson, Stephen Atkinson, Robert W. Hunter, Michael Allison, Andrew Austin, James W. Dear, Ewan Forrest, Tong Liu, Emma Lord, Steven Masson, Joao Nunes, Paul Richardson, Stephen D. Ryder, Mark Wright, Mark Thursz, Nikhil Vergis Alimentary Pharmacology & Therapeutics.2023; 58(11-12): 1217. CrossRef
Gut liver brain axis in diseases: the implications for therapeutic interventions Mengyao Yan, Shuli Man, Benyue Sun, Long Ma, Lanping Guo, Luqi Huang, Wenyuan Gao Signal Transduction and Targeted Therapy.2023;[Epub] CrossRef
Changes of the bacterial composition in duodenal fluid from patients with liver cirrhosis and molecular bacterascites Jim Höppner, Sandra Krohn, Ellen H. A. van den Munckhof, René Kallies, Adam Herber, Katharina Zeller, Jan Tünnemann, Madlen Matz-Soja, Antonis Chatzinotas, Stephan Böhm, Albrecht Hoffmeister, Thomas Berg, Cornelius Engelmann Scientific Reports.2023;[Epub] CrossRef
Current knowledge about biomarkers of acute kidney injury in liver cirrhosis Han Ah Lee, Yeon Seok Seo Clinical and Molecular Hepatology.2022; 28(1): 31. CrossRef
Pathogenic Mechanisms Underlying Cirrhotic Cardiomyopathy Hongqun Liu, Henry H. Nguyen, Ki Tae Yoon, Samuel S. Lee Frontiers in Network Physiology.2022;[Epub] CrossRef
Real‐world clinical features, health‐care utilization, and economic burden in decompensated cirrhosis patients: A national database Hankil Lee, Beom Kyung Kim Journal of Gastroenterology and Hepatology.2022; 37(11): 2154. CrossRef
Prolonged QT Interval in Cirrhosis: Twisting Time? William Lee, Bert Vandenberk, Satish R. Raj, Samuel S. Lee Gut and Liver.2022; 16(6): 849. CrossRef
New Evidence of Oral Branched-Chain Amino Acid Supplementation on the Prognosis of Patients With Advanced Liver Disease Hankil Lee, Jeong-Ju Yoo, Sang Hoon Ahn, Beom Kyung Kim Clinical and Translational Gastroenterology.2022; 13(12): e00542. CrossRef
Advances in cirrhotic cardiomyopathy Hongqun Liu, Ki Tae Yoon, Jing Zhang, Samuel S. Lee Current Opinion in Gastroenterology.2021; 37(3): 187. CrossRef
Background/Aims This study aimed to evaluate the efficacy and safety of emergency variceal ligation for the prevention of rebleeding in cirrhotic patients who are found on initial endoscopy to have blood clots in the stomach but no actively bleeding esophageal and gastric varices or stigmata.
Methods This study included 28 cirrhotic patients who underwent emergency prophylactic EVL and 41 who underwent an elective intervention between January 2009 and June 2014. Clinical outcomes were analyzed, including the rebleeding, 6-week mortality, and rebleeding-free survival rates.
Result s: The rebleeding rate was higher in the emergency than in the elective group (28.6% vs. 7.3%, P=0.041). Multivariate analysis showed that emergency prophylactic EVL (odds ratio [OR] = 7.4, 95% confidence interval [CI]=1.634.8, P=0.012) and Child-Pugh score C (OR=10.6, 95% CI=1.4-80.8, P=0.022) were associated with rebleeding. In the emergency group, the gastric varices were associated with rebleeding (OR=12.0, 95% CI=1.7-83.5, P=0.012).
Conclusions Emergency EVL may be associated with variceal rebleeding when blood clots are present in the stomach without active esophageal and gastric variceal bleeding or stigmata. Elective intervention should be considered as a safer strategy for preventing variceal rebleeding in this situation.
Citations
Citations to this article as recorded by
Combining endoscopic variceal ligation and omeprazole sodium in treating upper gastrointestinal hemorrhage combined with liver cirrhosis Changfang Xie, Shilei Gong, Zhenfeng Zhao, Lu Liu, Lu Lu, Jin Zhou, Xiaohuan Yu, Ying Xiong BMC Gastroenterology.2025;[Epub] CrossRef
Minimal and Maximal Extent of Band Ligation for Acute Variceal Bleeding during the First Endoscopic Session Jang Han Jung, Jung Hyun Jo, Sung Eun Kim, Chang Seok Bang, Seung In Seo, Chan Hyuk Park, Se Woo Park Gut and Liver.2022; 16(1): 101. CrossRef
Bedside risk‐scoring model for predicting 6‐week mortality in cirrhotic patients undergoing endoscopic band ligation for acute variceal bleeding Jung Hee Kim, Se Woo Park, Jang Han Jung, Da Hae Park, Chang Seok Bang, Chan Hyuk Park, Ji Won Park, Jae Gun Park Journal of Gastroenterology and Hepatology.2021; 36(7): 1935. CrossRef
Clinical outcomes of sedation during emergency endoscopic band ligation for variceal bleeding: Multicenter cohort study Chan Hyuk Park, Se Woo Park, Jang Han Jung, Gyeong Guk Kim, Se Young Choi, Eun Sun Kim, Dong Hyun In, Hong Deok Kim Digestive Endoscopy.2020; 32(6): 894. CrossRef
Endoscopic Removal of Inflated Transected Sengstaken–Blakemore Tube Using Endoscopic Scissors Jun Ho Lee, Eu-Kwon Hwang, Chanmesa Doeun, Jeong-Ju Yoo, Sang Gyune Kim, Young Seok Kim Clinical Endoscopy.2019; 52(2): 182. CrossRef
Current Perspectives Regarding Stem Cell-Based Therapy for Liver Cirrhosis Kyeong-Ah Kwak, Hyun-Jae Cho, Jin-Young Yang, Young-Seok Park Canadian Journal of Gastroenterology and Hepatology.2018; 2018: 1. CrossRef
Background/Aims It remains to be determined whether switching from adefovir (ADV) to tenofovir (TDF) provides better virological outcomes in patients exhibiting suboptimal responses to ADV plus nucleoside analogue (ADV+NA) therapy for NA-resistant chronic hepatitis B (CHB).
Methods In this prospective trial, patients who showed partial responses (defined as serum hepatitis B virus [HBV] DNA >60 IU/mL) to ADV+NA therapy for NA resistance were randomly allocated to receive TDF plus NA (TDF+NA group, n=16) or to continue their current therapy (ADV+NA group, n=16). The primary end point was the proportion of patients with complete virological response (CVR, defined as serum HBV DNA <60 IU/mL) at 48 weeks.
Result s: The median age was 52 years (16 men), and 28 were positive for hepatitis B e antigen (HBeAg). The baseline characteristics did not differ significantly between the two groups. The proportion with CVR was significantly higher in the TDF+NA group than in the ADV+NA group at 24 weeks (81.3% vs. 25.0%, P=0.001) and 48 weeks (87.5% vs. 37.5%, P=0.002). Furthermore, a decrease in the serum HBV DNA level of >2log10 IU/mL was more likely in the TDF+NA group at both 24 and 48 weeks (68.8% vs. 56.3%, P=0.014 vs. 81.3% vs. 56.3%, P=0.001, respectively). During the follow-up, the rate of HBeAg seroconversion was higher in the TDF+NA group than the ADV+NA group (12.5% vs. 6.25%, P=0.640), as was that for the hepatitis B surface antigen (6.25% vs. 0%, P=0.080). No serious adverse events due to antiviral agents occurred.
Conclusions In patients exhibiting suboptimal responses to ADV+NA therapy for NA-resistant CHB, switching from ADV to TDF might provide better virological outcomes.
Citations
Citations to this article as recorded by
Comparative efficacy and safety of pegylated interferon-alpha monotherapy vs combination therapies with entecavir or tenofovir in chronic hepatitis B patients Huiqing Liang, Xiaoting Zheng, Qianguo Mao, Jiaen Yang, Qingfa Ruan, Chuncheng Wu, Yaoyu Liu, Siyan Chen, Luyun Zhang, Manying Zhang, Hongli Zhuang, Li Lin, Shaodong Chen, Hyun Jin Kwun Microbiology Spectrum.2025;[Epub] CrossRef
Predictive value of hepatic, hematological, and immunological markers and their temporal dynamics in chronic hepatitis B functional cure Jianyong Zeng, Caixia Zheng, Yincheng Zheng, Xiulan Xue, Benjamin M. Liu Microbiology Spectrum.2025;[Epub] CrossRef
Entecavir versus tenofovir on the recurrence of hepatitis B–related HCC after liver transplantation: A multicenter observational study Deok-Gie Kim, YoungRok Choi, Jinsoo Rhu, Shin Hwang, Young Kyoung You, Dong-Sik Kim, Yang Won Nah, Bong-Wan Kim, Jai Young Cho, Koo Jeong Kang, Jae Do Yang, Donglak Choi, Dong Jin Joo, Myoung Soo Kim, Je Ho Ryu, Jae Geun Lee Liver Transplantation.2023; 29(12): 1272. CrossRef
KASL clinical practice guidelines for management of chronic hepatitis B
Clinical and Molecular Hepatology.2022; 28(2): 276. CrossRef
Is tenofovir and entecavir combination therapy still the optimal treatment for chronic hepatitis B patients with prior suboptimal response? Byoung Kuk Jang Clinical and Molecular Hepatology.2020; 26(3): 312. CrossRef
Long-term Efficacy of Tenofovir Disoproxil Fumarate Monotherapy for Multidrug-Resistant Chronic HBV infection Hye Won Lee, Jun Yong Park, Jin Woo Lee, Ki Tae Yoon, Chang Wook Kim, Hana Park, Young Seok Kim, Soon Ku Paik, Jung Il Lee, Beom Kyung Kim, Kwang-Hyub Han, Sang Hoon Ahn Clinical Gastroenterology and Hepatology.2019; 17(7): 1348. CrossRef
Comparison of the long-term efficacy of tenofovir and entecavir in nucleos(t)ide analogue-naïve HBeAg-positive patients with chronic hepatitis B Dachuan Cai, Chen Pan, Weihua Yu, Shuangsuo Dang, Jia Li, Shanming Wu, Nan Jiang, Maorong Wang, Zhaohua Zhang, Feng Lin, Shaojie Xin, Yongfeng Yang, Baoshen Shen, Hong Ren Medicine.2019; 98(1): e13983. CrossRef
Switching from tenofovir and nucleoside analogue therapy to tenofovir monotherapy in virologically suppressed chronic hepatitis B patients with antiviral resistance Dong Yun Kim, Hye Won Lee, Jeong Eun Song, Beom Kyung Kim, Seung Up Kim, Do Young Kim, Sang Hoon Ahn, Kwang‐Hyub Han, Jun Yong Park Journal of Medical Virology.2018; 90(3): 497. CrossRef
Step-down Strategy in Antiviral Resistant Chronic Hepatitis B Patients Who Achieved Viral Suppression With Rescue Combination Therapy Dong Yun Kim, Jun Yong Park Future Virology.2018; 13(10): 711. CrossRef
Efficacy and safety of three adefovir‐based combination therapies in HBeAg‐positive chronic hepatitis B patients with suboptimal response to adefovir monotherapy M.‐L. Wang, E.‐Q. Chen, D.‐M. Zhang, L.‐Y. Du, L.‐B. Yan, T.‐Y. Zhou, X.‐Z. Lei, B.‐J. Lei, J.‐J. Lu, J. Liao, H. Tang Journal of Viral Hepatitis.2017; 24(S1): 21. CrossRef
Young Mi Hong, Ki Tae Yoon, Mong Cho, Dae Hwan Kang, Hyung Wook Kim, Cheol Woong Choi, Su Bum Park, Jeong Heo, Hyun Young Woo, Won Lim, SM Bakhtiar UI Islam
Clin Mol Hepatol 2016;22(2):267-271. Published online May 16, 2016
The bone is a common site for metastasis in hepatocellular carcinoma (HCC). However, bone marrow metastasis from HCC is rarely reported, and its frequency is unclear. Here we report a rare case of bone marrow metastasis that presented as bicytopenia originating from HCC without bone metastasis. A 58-year-old man was admitted for investigation of a liver mass with extensive lymph node enlargement that was detected when examining his general weakness and weight loss. Laboratory findings revealed anemia, thrombocytopenia, mild elevated liver enzymes, normal prothrombin time percentage and high levels of tumor markers (α-fetoprotein and des-γ-carboxyprothrombin). Abdominal computed tomography showed multiple enhanced masses in the liver and multiple enlarged lymph nodes in the abdomen. A bone marrow biopsy revealed only a few normal hematopoietic cells and abundant tumor cells. Despite its rarity, bone marrow metastasis should always be suspected in HCC patients even if accompanied by cirrhosis.
Citations
Citations to this article as recorded by
Case Report: A rare case of MET-amplified gastric cancer with systemic metastasis: remarkable efficacy of crizotinib and the role of precision medicine Yan Shen, Yaxin Xu, Jing Sun Frontiers in Oncology.2025;[Epub] CrossRef
Comprehensive review of solid tumor bone marrow metastasis Lanxin Zhang, Fengxi Chen, Lingzhi Xu, Ning Li, Qiping Zhuo, Yijin Guo, Xueqing Wang, Meijie Wen, Zuowei Zhao, Man Li Critical Reviews in Oncology/Hematology.2024; 194: 104248. CrossRef
Mechanism and clinical progression of solid tumors bone marrow metastasis Ruohan Yang, Lin Jia, Jiuwei Cui Frontiers in Pharmacology.2024;[Epub] CrossRef
Clinical features and treatment of bone marrow metastasis Hongliang Yang, Feng He, Tian Yuan, Wen Xu, Zeng Cao Oncology Letters.2023;[Epub] CrossRef
A case of bone marrow metastasis of hepatocellular carcinoma diagnosed by fluorodeoxyglucose-positron emission tomography Naomi Matsutani, Yuichiro Yokoyama, Shogo Shiratsuki, Shinya Kuwashiro, Kosuke Okita, Taro Takami, Isao Sakaida Kanzo.2022; 63(1): 16. CrossRef
Rare Site Hepatocellular Carcinoma Metastasis
Enrique Boldo, Ana Santafe, Araceli Mayol, Rafael Lozoya, Alba Coret, Diana Escribano, Carlos Fortea, Andres Muñoz, Juan Carlos Pastor, Guillermo Pérez de Lucia, Nuria Bosch Aparicio Journal of Hepatocellular Carcinoma.2020; Volume 7: 39. CrossRef
Presumed disseminated carcinomatosis of the bone marrow in a dog Bárbara Andreia Jardim Gomes, Eilidh Gunn, Caroline Millins, Elspeth M Waugh, Gawain Hammond Veterinary Record Case Reports.2020;[Epub] CrossRef
Cordycepin suppresses the migration and invasion of human liver cancer cells by downregulating the expression of CXCR4 Zhongrong Guo, Wen Chen, Guisen Dai, Yuanliang Huang International Journal of Molecular Medicine.2019;[Epub] CrossRef
A rare case of infiltrative hepatocellular carcinoma presented with neck mass Yu‐Kwang Lee, Chung‐Chieh Wang, Yu‐Tse Chiu, Tai‐Chung Tseng Advances in Digestive Medicine.2021; 8(1): 51. CrossRef
Screening, clinical features and prognostic analysis of liver cirrhosis-related hepatocellular carcinoma Zhengwei Zha, Wenyue Wu, Qianqian Zhang, Xi Wang, Xuecan Mei, Yi Xiang, Derun Kong Scandinavian Journal of Gastroenterology.2021; 56(8): 948. CrossRef
LINC01287 regulates tumorigenesis and invasion via miR‐298/MYB in hepatocellular carcinoma Yichao Mo, Longguang He, Zeru Lai, Zhiheng Wan, Qinshou Chen, Sibo Pan, Liangfu Li, Dasheng Li, Junwei Huang, Fan Xue, Siyao Che Journal of Cellular and Molecular Medicine.2018; 22(11): 5477. CrossRef
Application of contrast‑enhanced ultrasound and enhanced CT in diagnosis of liver cancer and evaluation of radiofrequency ablation Shuhong Kong, Xuewang Yue, Sheng Kong, Yujie Ren Oncology Letters.2018;[Epub] CrossRef
Study on the diagnosis of small hepatocellular carcinoma caused by hepatitis B cirrhosis via multi‑slice spiral CT and MRI Mei Wang, Congxin Wei, Zhaojuan Shi, Jianzhong Zhu Oncology Letters.2017;[Epub] CrossRef
First
Prev
